Evidence map›Paper›PMID 41563231›Full record

ArticleInternational journal of radiation oncology, biology, physics2026

Pretreatment Chromosomal Instability Correlates With Radiation Sensitivity in Squamous Cell Cancers.

Pippa F Cosper, Maha Paracha, Kathryn M Jones, Laura Hrycyniak, Les Henderson, Ava Bryan, Diego Eyzaguirre, Emily McCunn, Elizabeth Boulanger, Jun Wan and 6 more

Abstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Pippa F CosperDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin. Electronic address: cosper@wisc.edu.
Maha ParachaDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin.
Kathryn M JonesDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin.
Laura HrycyniakMolecular and Cellular Pharmacology Graduate Training Program, University of Wisconsin, Madison, Wisconsin.
Les HendersonWisconsin State Laboratory of Hygiene, University of Wisconsin, Madison, Wisconsin.
Ava BryanDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin.
Diego EyzaguirreDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin.
Emily McCunnDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin.
Elizabeth BoulangerDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin.
Jun WanPhysiology Graduate Training Program, University of Wisconsin-Madison, Madison, Wisconsin.
Kwangok P NickelDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin.
Vanessa HornerWisconsin State Laboratory of Hygiene, University of Wisconsin, Madison, Wisconsin.
Rong HuDepartment of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Paul M HarariDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Randall J KimpleDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin; University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Beth A WeaverUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin; Department of Cell and Regenerative Biology, University of Wisconsin-Madison, Madison, Wisconsin; Department of Oncology/McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin. Electronic address: baweaver@wisc.edu.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptorsP50CA278595 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI David J Beebe · 2022 to 2026
$12.5M
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI HARARI, PAUL M · 2016 to 2020
$10.8M
Training in Cancer Biology Training GrantT32CA009135 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SUGDEN, WILLIAM M. · 1985 to 2024
$10.4M
Improving the translational value of head and neck cancer patient-in-mouse modelsR37CA255330 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Randall J. Kimple · 2021 to 2026
$3.5M
Mechanisms of paclitaxel sensitivity and resistanceR01CA284747 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Mark E Burkard, Beth A Weaver · 2024 to 2026
$1.6M
Chromosomal Instability as a Marker and Mechanism of Radiation ResponseK08CA256166 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI COSPER, PIPPA F · 2021 to 2025
$926k
Head and Neck squamous cell carcinoma radiation response modulation by HPVR00CA160639 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KIMPLE, RANDALL J. · 2013 to 2015
$725k
Automated Tissue MicroarrayerS10OD023526 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI MATKOWSKYJ, KRISTINA A. · 2018 to 2018
$184k
NCI NIH HHS K08 CA256166NCI NIH HHS P30 CA014520NCI NIH HHS P50 CA278595NCI NIH HHS R00 CA160639NCI NIH HHS R01 CA284747NCI NIH HHS R37 CA255330NCI NIH HHS T32 CA009135NIDCR NIH HHS P50 DE026787NIH HHS S10 OD023526
6 · The paper itself

Abstract

purposeContinuous chromosome missegregation over successive mitotic divisions, known as chromosomal instability (CIN), is common in cancer. Though it has been associated with treatment resistance and poor prognosis, increasing CIN above a maximally tolerated threshold leads to cell death because of loss of essential chromosomes. Because radiation causes CIN, we hypothesize that pre-existing CIN sensitizes tumor cells to radiation therapy. METHODS AND MATERIALS: We induced mitotic defects that lead to CIN in FaDu (head and neck cancer, HNC) and HeLa (cervical) cells by knocking down or overexpressing the mitotic checkpoint protein mitotic arrest deficient 1 (Mad1), which induces lagging chromosomes. Radiation sensitivity was tested with clonogenic assays in vitro and tumor regression in patient-derived xenografts in vivo. MTT assays were used to determine the sensitivity of human papillomavirus (HPV) positive and HPV-negative HNC cells to docetaxel, and mitotic defects were quantified using immunofluorescence microscopy. Docetaxel-induced mitotic errors and tumor growth delay were evaluated in vivo. Six-chromosome fluorescence in situ hybridization was used to quantify CIN in a cohort of patients with laryngeal cancer treated with definitive radiation.

resultsHere, we show in two tissue contexts using engineered isogenic cancer cell lines that higher rates of chromosome missegregation sensitize to ionizing radiation, which itself induces mitotic errors. Consistent with this result, higher rates of anaphase defects in HPV-positive and HPV-negative HNC patient-derived xenograft tumors correlate with response to radiation. Moreover, laryngeal tumors with higher CIN before treatment tend to have an improved response to radiation therapy in the clinic. Furthermore, we show that docetaxel, a microtubule-stabilizing drug commonly used in combination with radiation, causes cell death and radiosensitizes cells by inducing abnormal multipolar spindles rather than causing mitotic arrest.

conclusionsThese results mechanistically implicate CIN as an inducer of radiation response and provide evidence that increasing the rate of CIN is a rational method to enhance radiation sensitivity, which has significant implications for personalized therapy.

Indexed as

Carcinoma, Squamous CellChromosomal InstabilityHead and Neck NeoplasmsLaryngeal NeoplasmsRadiation ToleranceAnimalsCell Cycle ProteinsCell Line, TumorDocetaxelHeLa CellsHuman Papillomavirus VirusesHumansIn Situ Hybridization, FluorescenceMiceMitosisTaxoidsCell Cycle ProteinsDocetaxelTaxoids

Identifiers

PMID41563231
PMCPMC13154730

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.